26B-4-243. Guidance for treatment with medical cannabis.
The department, in consultation with the Center for Medical Cannabis Research created in Section, shall:
(1) develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include: for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis; risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration;
(2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding: the evidence-based guidance for treatment with medical cannabis described in Subsection; (1)(a) relevant warnings and safety information related to medical cannabis use; and other topics related to medical cannabis use as determined by the department; and
(3) develop patient product information inserts for medical cannabis products: in consultation with the cannabis processing facility that created the product; and that do not contain proprietary information about the product.